Identification of a novel tyrosine kinase inhibitor for acute myeloid leukemia

March 17, 2016

Acute myeloid leukemia (AML) is a cancer of myeloid stem cells that develops in both adult and pediatric populations. Mutations that cause hyperactivation of the FMS-like tyrosine kinase 3 (FLT3) are commonly found in AML, and several clinical trials are testing FLT3 inhibitors. However, resistance to FLT3 inhibitors can develop, highlighting the need for additional approaches to treating AML.

Douglas Graham of the University of Colorado and colleagues at the University of North Carolina and UCSF report in JCI Insight the development of a new drug that targets both resistant tumors and FLT3-independent AML. This research group previously documented that the receptor MERTK is elevated in the majority of acute leukemias.

They now show in culture and in preclinical models that the newly developed compound MRX-2843 exerts antitumor effects. Using a xenograft model in which patient-derived AML cells were injected into mice, they found that MRX-2843 treatment improved survival, even in cases of tumors resistant to the FLT3 inhibitor quizartinib.

Collectively, this study provides rationale for further exploring the clinical utility of MRX-2843.

Explore further: Phase I clinical trial of anti-cancer drug FF-10101 in patients with relapsed or refractory acute myeloid leukemia

More information: Katherine A. Minson et al. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia, JCI Insight (2016). DOI: 10.1172/jci.insight.85630

Related Stories

A new target in acute myeloid leukemia

July 16, 2012

Acute myeloid leukemia, a common leukemia in adults, is characterized by aberrant proliferation of cancerous bone marrow cells. Activating mutations in a protein receptor known as FLT3 receptor are among the most prevalent ...

Normal enzyme aids a mutant one to fuel blood cancer's growth

February 10, 2014

Reinforcing the need to look beyond genomic alterations to understand the complexity of cancer, researchers from Dana-Farber/Boston Children's Cancer and Blood Disorders Center report that a normal enzyme called SYK pairs ...

Recommended for you

Deworming pill may be effective in treating liver cancer

March 30, 2017

Hepatocellular carcinoma (HCC), a cancer associated with underlying liver disease and cirrhosis that often only becomes symptomatic when it is very advanced, is the second leading cause of cancer deaths around the world, ...

Study shows how BPA may affect inflammatory breast cancer

March 29, 2017

The chemical bisphenol A, or BPA, appears to aid the survival of inflammatory breast cancer cells, revealing a potential mechanism for how the disease grows, according to a study led by researchers in the Department of Surgery ...

Gene research gives new insight into pancreatic cancer

March 29, 2017

One reason pancreatic cancer has a particularly low survival rate is the difficulty in getting drugs to the tumour, but new knowledge of how pancreatic cancer cells invade neighbouring cells could change that.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.